| Ytd | -10.99% | |
| 1y | 138.95% |
| Open | 3.67 | Prev Close | 3.69 | Low | 3.63 | High | 3.69 | Mkt Cap | 348.04M |
| Vol | 21.89K | Avg Vol | 644.34K | EPS | -4.54 | P/E | -0.81 | Forward P/E | -1.23 |
| Beta | 0.35 | Short Ratio | 8.64 | Inst. Own | 67.66% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 4.02 | 200-d Avg | 3.84 | 1yr Est | 3.05 |
XFOR News
Wells Fargo analyst Derek Archila initiates coverage on X4 Pharmaceuticals (NASDAQ:XFOR) with a O
BOSTON, July 07, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im
BOSTON, July 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im
BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on im
BOSTON, May 27, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on imp
X4 Pharmaceuticals (XFOR) witnesses a hammer chart pattern, indicating support found by the stock af
X4 Pharmaceuticals (XFOR) might move higher on growing optimism about its earnings prospects, which
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.16 per share versus the Zacks Consens
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment by the end of Q3 20
- European Commercialization will be Led by X4 Pharmaceuticals' Partner, Norgine - - Global, Pivota
BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i
X4 Pharmaceuticals (XFOR) came out with a quarterly loss of $0.22 per share versus the Zacks Consens
- Global 4WARD Phase 3 Chronic Neutropenia Trial On Track to Complete Enrollment in Q3 2026 - - Posi
Analyst sentiment across three small-cap biotechs has turned notably positive, with fresh coverage i
BOSTON, March 04, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i
X4 Pharmaceuticals (XFOR) is rated BUY, driven by a funded Phase 3 trial, current product pipeline,
BOSTON, March 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company focused on i
- Potential First and Only Therapy in the EU for Ultra-Rare Immune Disorder - BOSTON, Feb. 27, 2026
X4 Pharmaceuticals, Inc. (XFOR) Presents at Guggenheim Securities Emerging Outlook: Biotech Summit 2
BOSTON, Feb. 03, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to imp
BOSTON, Feb. 02, 2026 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to imp
On Thursday, 588 stocks hit new 52-week lows.
On Friday, 1043 companies hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.
Companies Reporting Before The Bell • DISH Network (NASDAQ:DISH) is likely to report quarterly e
Companies Reporting Before The Bell • Mastercard Inc. (NYSE:MA) is expected to report quarterly ear
Stocks That Hit 52-Week Lows On Wednesday